Tirzepatide FAERS Reports Across Sixteen Quarters: Volume, Terms, and Reporting Mix

FAERS contains 171,797 tirzepatide-matched reports received from July 2022 through June 2026. Quarterly volume increased from 1,244 reports in 2022 Q3 to 21,079 in 2026 Q2. The serious share increased from 7.2 to 23.6 percent, while the share containing dose or injection-site terms declined from 45.1 to 21.8 percent. United States reports declined from 100.0 to 89.2 percent of quarterly volume. The serious share also increased within United States reports and within United States consumer reports. Report composition changed across the sixteen quarters, but the archive cannot identify whether exposure, indication, product use, reporter mix, follow-up, or clinical events produced the change.

1. Cohort and term rules

The cohort includes reports whose searchable drug and reaction fields contain tirzepatide and whose FDA received date falls from 1 July 2022 through 30 June 2026. One row is a submitted report, not a confirmed patient or causal event. Dose or injection-site presence means that at least one reported reaction term contains “dose” or “injection site.” This narrow rule excludes other device and administration concepts.

2. Quarterly report volume increased seventeen-fold

Quarterly volume rose from 1,244 reports in 2022 Q3 to 21,079 in 2026 Q2. The series is not monotonic, with declines in 2023 Q4 and 2024 Q2. Volume first exceeded 10,000 in 2024 Q1 and exceeded 20,000 in 2026 Q1. Report counts reflect exposure, market growth, reporting behavior, product attention, and submission practices alongside adverse events.

3. Serious and dose-related shares moved in opposite directions

The serious share increased from 7.2 percent in 2022 Q3 to 23.6 percent in 2026 Q2. The dose or injection-site share increased early, reached 62.0 percent in 2024 Q1, and declined to 21.8 percent by 2026 Q2. The curves describe a shift in submitted term and flag composition. They do not show that administration problems resolved or clinical risk increased.

4. Reporting geography changed across the series

United States reports account for 100.0 percent of the first quarter and 89.2 percent of the last. The share first falls below 95 percent in 2024 Q3 and reaches 86.6 percent in 2025 Q4. Non-US FAERS reports carry substantially different serious-selection patterns, so the changing country mix raises the crude serious share independently of molecule effects.

5. Consumer reports remained the dominant qualification

Consumers account for more than 90 percent of reports in fourteen of sixteen quarters. Their share is 91.6 percent in 2022 Q3, peaks at 93.7 percent in 2023 Q2, and declines to 82.1 percent in 2026 Q2. Reporter qualification therefore changes less than geography until the final quarter, but its late decline can affect both term selection and serious flags.

6. The serious-share increase remains within reporting groups

Within United States reports, the serious share rises from 7.2 percent in 2022 Q3 to 14.5 percent in 2026 Q2. Within United States consumer reports, it rises from 6.7 to 11.2 percent. Restricting both geography and qualification reduces the level and range but does not remove the increase. Unmeasured shifts in indication, age, comorbidity, drug burden, organization, and follow-up can still remain.

7. Supported interpretation

The record supports three conclusions within its reporting limits. Tirzepatide-matched quarterly report volume increased substantially across sixteen quarters. Dose or injection-site terms declined while serious flags increased. Geography explains part of the crude serious-share rise, but the increase remains within United States and United States consumer reports. The data support a changing report profile, not a general maturation law or a causal safety trend.

8. Limitations

Received date can differ from event date. Reports can be duplicated, revised, delayed, and stimulated by publicity or litigation. The term rule is a narrow text classification and differs from broader administration-term definitions. Country and qualification restrictions do not control product formulation, indication, dose, patient characteristics, concomitant drugs, or reporting organization. Later extracts can revise historical records.